Table 2.

Data of imatinib, sunitinib and sorafenib treatment.

Treatment data	Imatinib	Sunitinib	Sorafenib
No. of patients	1047	456	137
No. of complete observations (%)	587 (56.1)	299 (65.6)	67 (48.9)
Median observation time (months) [95% CI]	71 [64.8–79.2]	41.4 [34.6–49.3]	17.4 [14.6–22.9]
Median overall survival (months) [95% CI]	56.9 [50.4–61.2]	22.8 [19.2–26.8]	16.9 [13.7–24.3]
Probability of surviving 12 months (%)	89.5	68.2	61.9
Probability of surviving 24 months (%)	77.9	47.1	36.2
Probability of surviving 36 months (%)	66.9	31	16.8
Probability of surviving 60 months (%)	48.4	Not reached	Not reached

CI – confidence interval.